Organon Follistim (follitropin beta) to be launched week of Oct. 6; Serono Gonal-F also approved Sept. 29.
Executive Summary
ORGANON FOLLISTIM AND SERONO GONAL-F CONVENIENCE AND PURITY TO RECEIVE EMPHASIS in upcoming promotional campaigns for the recombinant follitropin products, which received FDA approval Sept. 29. The companies will be focusing on purity and convenience of administration, because the safety and efficacy of the new recombinant products is similar to that of the older menotropins and urofollitropin fertility drugs (Organon's Humegon and Serono's Metrodin).